2026 article

Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers

Vasily Giannakeas, Adriana I. Apostol, Claudia Diella, Nupur Dave, Jacek Gronwald, Robert Fruscio, Beth Y. Karlan, Cezary Cybulski, Christian F. Singer, Pål Møller, Raymond H. Kim, Louise Bordeleau, Teresa Ramón y Cajal, Tuya Pal, Andrea Eisen, Fergus J. Couch, Dana Zakalik, Kelly Metcalfe, Nadine Tung, Amber Aeilts, Ping Sun, Jan Lubinski, Joanne Kotsopoulos, Steven A. Narod, Kevin Sweet, Christine Elser, Seema Panchal, Georgia Wiesner, Susan Armel, Linda Steele, Howard Saal, Kim Serfas, Carey A. Cullinane, Robert E. Reilly, Daniel Rayson, Leanne Mercer, Jeffrey Dungan, Stephanie Cohen, Susan Neuhausen, Sophie Sun, Leigha Senter, Joanne L Blum, Klaudia Stempa, Willam Foulkes, Olufunmilayo Olopade, Edmond Lemire, Stefania Zovato, Antonella Rastelli, Michelle Jacobson, Tracy Graham, Intan Schraeder

0Citations signalées, ce qui n’est pas une note de qualité

28Institutions déclarées

8Pays d’affiliation déclarés

Rattachement africain : ca, it, pl, us, at, no, fi, es. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Importance: Women with a BRCA1 or BRCA2 variant face a high lifetime risk of ovarian cancer and are often advised to undergo preventive surgery (bilateral salpingo-oophorectomy [BSO]) before cancer develops. The recommended age of BSO is 35 years for BRCA1 carriers and is 45 years for BRCA2 carriers, but some women choose to delay surgery until the age of menopause; there is no standard upper age at which surgery is no longer advised. Objective: To estimate the residual lifetime risk of ovarian cancer among BRCA carriers by current age and projected age at BSO. Design, Setting, and Participants: This was a prospective cohort study in an international cohort of BRCA carriers monitored for incident ovarian cancer. A life table analysis used age-specific ovarian cancer incidence rates and competing mortality rates to estimate lifetime risk of ovarian cancer among women with a BRCA1 or BRCA2 pathogenic variant with both ovaries intact and no prior ovarian cancer at baseline. Patients were recruited between 1995 and 2024 across 24 international centers, and the mean (SD) follow-up was 4.4 (3.9) years. Exposure: Timing of BSO, defined as immediate BSO, delayed BSO, or no BSO. Main Outcome and Measures: Residual lifetime risk of ovarian cancer. Results: The cohort consisted of 4286 BRCA1 and 1427 BRCA2 carriers between the ages of 30 and 74 years at baseline (mean [SD] age, 42.0 [10.8] years). There were 249 incident ovarian cancers in the follow-up period. The lifetime risk of ovarian cancer was 55.0% (95% CI, 48.8-61.9) for a BRCA1 carrier and 24.1% (95% CI, 15.1-36.6) for a BRCA2 carrier. A 30-year-old BRCA1 carrier with BSO delayed to age 50 years had a projected residual ovarian cancer risk of 23.9% (95% CI, 20.7-27.4). At age 75 years, the residual risk of ovarian cancer was estimated to be 8.4% (95% CI, 1.7-22.7) for a BRCA1 carrier and 3.7% (95% CI, 0.1-22.7) for a BRCA2 carrier. Conclusions and Relevance: The residual risk of ovarian cancer for older women in good health is sufficiently high to consider preventive surgery. BRCA1 carriers who defer BSO until age 50 years may face a substantial risk of developing ovarian cancer.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers
Date Crossref: 23/09/2026
Éditeur: American Medical Association (AMA)
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

University of Toronto Department of Medical Oncology pays non établi dans la notice
Université ou école supérieure
Lunenfeld-Tanenbaum Research Institute Now with Prosserman Centre for Population Health Research pays non établi dans la notice
Structure de recherche
Women's College Hospital pays non établi dans la notice
Établissement de santé
Public Health Ontario pays non établi dans la notice
Établissement de santé
Agostino Gemelli University Polyclinic pays non établi dans la notice
Établissement de santé
International Hereditary Cancer Center pays non établi dans la notice
Établissement de santé
Pomeranian Medical University Department of Genetics and Pathology pays non établi dans la notice
Université ou école supérieure
Azienda Ospedaliera San Gerardo pays non établi dans la notice
Établissement de santé
University of Milano-Bicocca pays non établi dans la notice
Université ou école supérieure
University of California pays non établi dans la notice
Université ou école supérieure
Comprehensive Cancer Center Vienna pays non établi dans la notice
Établissement de santé
Medical University of Vienna Department of Obstetrics and Gynecology and Comprehensive Cancer Center pays non établi dans la notice
Université ou école supérieure

Department of Medical Oncology — University of Toronto, Now with Prosserman Centre for Population Health Research — Lunenfeld-Tanenbaum Research Institute et Women's College Hospital, avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

BRCA gene mutations in cancerOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Consulter la publication primaire Ouvrir le DOI